Drug Search Results
More Filters [+]

SB-1578

Alternative Names: sb-1578, sb1578, sb 1578
Latest Update: 2012-04-20
Latest Update Note: Clinical Trial Update

Product Description

SB1578 is a novel, orally bioavailable JAK2 inhibitor with specificity for JAK2 within the JAK family and also potent activity against FLT3 and c-Fms. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22962687/)

Mechanisms of Action: JAK2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: S*BIO
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SB-1578

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SB1578-2010-001

P1

Completed

Healthy Volunteers

2011-03-01

Recent News Events

Date

Type

Title